Plasma‐derived medicinal products (PDMPs), particularly immunoglobulins (Igs), play a crucial role in treating rare, severe, often genetically inherited conditions such as primary immunodeficiencies (PID), haemophilia, alpha‐1 antitrypsin deficiency (AATD) and hereditary angioedema (HAE) and neurological disorders such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), myasthenia gravis (MG), multifocal motor neuropathy (MMN) and Guillain‐Barré syndrome (GBS) [1, 2, 3]. Here, CUBN is linked to chronic inflammatory demyelinating polyradiculoneuropathy.